More rumors tie Allergan to Shire; Actelion could be a takeout target;

@FierceBiotech: Meet the new Novartis: Slimmer structure, same R&D commitment. More | Follow @FierceBiotech

@JohnCFierce: For everyone in San Diego or coming next week: Killer weather, the kind that makes you want to move here. | Follow @JohnCFierce

@DamianFierce: Rebuffed in its attempt on AstraZeneca's cancer pipeline, Pfizer teams with Cellectis for immunotherapies of its own. Story | Follow @DamianFierce

> Shire's ($SHPG) shares jumped once again on the heels of a SunTrust report that Allergan ($AGN) was nigh on making an offer for the company. News

> Actelion ($ATLN) could be a hot M&A target thanks to its recent clinical success with the pulmonary arterial hypertension drug selexipag. Story

> Microbiome biotech Enterome has teamed up with the Mayo Clinic to co-develop diagnostic tests. Item

Medical Device News

@FierceMedDev: Obesity device before FDA panel despite not meeting primary endpoints - FierceMedicalDevices. Story | Follow @FierceMedDev

@StacyALawrence: 3-D printer Materialise slated to price $104M IPO - FierceMedicalDevices. More | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats #Parkinsons with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Chrono Therapeutics tackles smoking cessation with programmable monitoring system. Article from FierceDrugDelivery | Follow @EmilyWFierce

> Medtronic merger could give Covidien execs an $80M payout. More

> Another FDA setback for Boston Scientific's Watchman stroke-fighting device. Story

> Lawmakers question FDA oversight of mobile medical apps as market booms. Article

Pharma News

@FiercePharma: Top-read special report Monday: The top 10 best-selling diabetes drugs of 2013. Report | Follow @FiercePharma

@TracyStaton: Trending now @FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: #OSHA seeks $500,000 in penalties against #API maker that no longer exists but it was bad player when it did. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer puts the heat on Novartis with FDA MenB filing. Story from FierceVaccines | Follow @CarlyHFierce

@JustinHFierce: China-manufactured weight loss drug Sport Burner has Prozac in it, icymi, says @FDArecallsNotification | Follow @JustinHFierce

> Could Actelion and Cipla be next on Big Pharma's M&A takeover list? Story

> CEO: New Novartis will be a lean, mean, profit-making machine. More

> Generics snafus give Big Pharma a windfall, but cost U.S. patients billions. Article

Drug Delivery News

> Protein from a fatal fungus may offer up meningitis treatment. Story

> Chrono Therapeutics tackles smoking cessation with programmable monitoring system. More

> Proteasome inhibitor delivered with cancer-killing viruses enhances effect. Item

> 'Onion' drug delivery vehicle has concentric layers for consistent dosing. Article

Diagnostics News

> Sequenom enlists Quest to help market its prenatal test. More

> Alere gets FDA clearance for rapid influenza test. Story

> Natera puts its prenatal know-how toward cancer diagnostics. Article

> Enterome teams up with Mayo for gut diagnostics. Report

> Navidea bags expanded FDA nod for Lymphoseek. News

> Israeli bladder cancer Dx outfit raises $5M in financing. Item

Pharma Marketing News

> Fake patient story wins a real-life marketing award? Discuss. Story

> How to speak on social media? Finally, the FDA offers more specific clues. More

> Today's pharma reps need the skills of doctors, lawyers, beggars--but not thieves. Article

> Pfizer, Novartis square off for tussle in meningitis vaccine market. Story

> J&J recruits a Hispanic family to be its reps in the Hispanic market. News

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.